Literature DB >> 16985886

alpha-Blockers for Treatment of the Prostatitis Syndromes.

J Curtis Nickel.   

Abstract

The prostatitis syndromes are among the most common and frustrating clinical challenges for urologists in outpatient practice. Available treatment, especially for the chronic prostatitis syndromes, is poor, with no standard therapy producing significant cure rates. alpha-Blocker therapy has been advocated (with various levels of evidence) as a treatment modality for all categories of the prostatitis syndromes. This article reviews the evidence supporting the use of alpha-blocker therapy in patients with prostatitis. Further trials of longer duration, perhaps employing combination therapies, are indicated to better evaluate the role of alpha-blockers in the management of the prostatitis syndromes.

Entities:  

Year:  2005        PMID: 16985886      PMCID: PMC1477636     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  30 in total

1.  Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Daniel A Shoskes; Lawrence Hakim; Gamal Ghoniem; Charles L Jackson
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

Review 2.  Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network.

Authors:  J C Nickel; L M Nyberg; M Hennenfent
Journal:  Urology       Date:  1999-08       Impact factor: 2.649

3.  Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study.

Authors:  R G Prosnitz; L Schneider; J Manola; S Rocha; M Loffredo; L Lopes; A V D'Amico
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

4.  Temporal resolution of urinary morbidity following prostate brachytherapy.

Authors:  G S Merrick; W M Butler; J H Lief; A T Dorsey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-04-01       Impact factor: 7.038

5.  Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial.

Authors:  Richard B Alexander; Kathleen J Propert; Anthony J Schaeffer; J Richard Landis; J Curtis Nickel; Michael P O'Leary; Michel A Pontari; Mary McNaughton-Collins; Daniel A Shoskes; Craig V Comiter; Nand S Datta; Jackson E Fowler; Robert B Nadler; Scott I Zeitlin; Jill S Knauss; Yanlin Wang; John W Kusek; Leroy M Nyberg; Mark S Litwin
Journal:  Ann Intern Med       Date:  2004-10-19       Impact factor: 25.391

6.  How common is prostatitis? A national survey of physician visits.

Authors:  M M Collins; R S Stafford; M P O'Leary; M J Barry
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

7.  Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.

Authors:  Aare Mehik; Peeter Alas; J Curtis Nickel; Ari Sarpola; Pekka J Helström
Journal:  Urology       Date:  2003-09       Impact factor: 2.649

8.  Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial.

Authors:  Phaik Yeong Cheah; Men Long Liong; Kah Hay Yuen; Chu Leong Teh; Timothy Khor; Jin Rong Yang; Hin Wai Yap; John N Krieger
Journal:  J Urol       Date:  2003-02       Impact factor: 7.450

9.  Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.

Authors:  J J de la Rosette; H F Karthaus; P E van Kerrebroeck; T de Boo; F M Debruyne
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

Review 10.  Clinical evaluation of the man with chronic prostatitis/chronic pelvic pain syndrome.

Authors:  J Curtis Nickel
Journal:  Urology       Date:  2002-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.